6-K

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of June 2020

Commission File Number: 001-39131

LIMINAL BIOSCIENCES INC.

(Translation of registrant’s name into English)

440 Armand-Frappier Boulevard, Suite 300

Laval, Québec

H7V 4B4

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:  

☒ Form 20-F   ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

INCORPORATION BY REFERENCE

Exhibits 99.1 and 99.2 are hereby expressly incorporated by reference into the registrant’s registration statement on Form S-8 filed with the Securities and Exchange Commission on December 23, 2019 (File no. 333-235692).

EXHIBIT LIST

Exhibit	Description
99.1	Articles of Amendment dated June 16, 2020
99.2	Amendments to By-law No.1 dated June 8, 2020

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Liminal BioSciences Inc.
Date: June 18, 2020	By:	/s/ Kenneth Galbraith
		Name	Kenneth Galbraith
		Title:	Chief Executive Officer

 

EX-99.1

  Exhibit 99.1

Certificate of Amendment Canada Business Corporations Act Certificat de modification Loi canadienne sur les sociétés par actions

Liminal BioSciences Inc.

Corporate name / Dénomination sociale

307730-6

Corporation number / Numéro de société

I HEREBY CERTIFY that the articles of the above-named corporation are amendedunder section 178 of the Canada Business Corporations Act as set out in the attached articles ofamendment. JE CERTIFIE que les statuts de la société susmentionnée sont modifiés aux termes de l'article 178 de la Loi canadienne sur les sociétés par actions, tel qu'il est indiqué dansles clauses modificatricesci-jointes.

Raymond Edwards

Director / Directeur

2020-06-16

Date of amendment (YYYY-MM-DD)

Date de modification (AAAA-MM-JJ)

Form4 ArticlesofAmendment Canada Business CorporationsAct (CBCA) (s. 27 or177) Formulaire4 Clausesmodificatrices Loi canadienne sur les sociétés par actions (LCSA) (art. 27 ou 177)

1	Corporatename Dénominationsociale Liminal BioSciencesInc.
2	Corporationnumber Numérodelasociété 307730-6
3	Thearticlesareamendedasfollows Lesstatutssontmodifiésdelafaçonsuivante
	Thecorporationamendstheotherprovisionsasfollows: Lesautresdispositionssontmodifiéescommesuit: Seeattachedschedule /Voirl'annexeci-jointe
4	Declaration:I certifythatI amadirectoror anofficerof thecorporation. Déclaration:J’attestequejesuisun administrateurou un dirigeantdelasociété.

Originalsigned by /Originalsigné par

Marie Iskra

Marie Iskra

450-781-0115

Misrepresentationconstitutesanoffenceand,on summaryconviction,apersonisliabletoafinenotexceeding$5000 or toimprisonmentfor atermnotexceedingsixmonthsor both(subsection250 (1) of theCBCA).

Faireunefaussedéclarationconstitueuneinfractionetson auteur,sur déclarationdeculpabilitéparprocéduresommaire,estpassibled’uneamendemaximalede5 000 $ etd’un emprisonnement maximaldesixmois,ou l’unedecespeines(paragraphe250(1) delaLCSA).

You areprovidinginformationrequiredby theCBCA.NotethatboththeCBCAandthePrivacyActallowthisinformationtobedisclosedtothepublic.Itwillbestoredinpersonalinformationbank numberIC/PPU-049.

Vous fournissezdesrenseignementsexigésparlaLCSA.IlestànoterquelaLCSAetlaLoisur lesrenseignementspersonnelspermettentquedetelsrenseignementssoientdivulguésaupublic.Ils serontstockésdanslabanquederenseignementspersonnelsnuméroIC/PPU-049.

IC3069 (2008/04)

Schedule/Annexe

OtherProvisions/Autresdispositions

Thearticlesare amended by adding:

Meetingsofshareholders oftheCorporationmay be held atthefollowingplaces outside Canada:

Boston,MA,U.S.

New York,NY,U.S.

SanFrancisco,CA,U.S.

London,U.K.

Cambridge, U.K.

EX-99.2

Exhibit 99.2

LIMINAL BIOsciences inc.

Amendments to By-law No.1 of the Corporation

(adopted by the Board of Directors on March 16, 2020 and April 3, 2020)

(approved, ratified and confirmed by the shareholders on June 8, 2020)

IT WAS RESOLVED THAT:

1. the amendment to By-law No. 1 of the Corporation relating to the conduct of internal affairs by replacing Section 3.2 thereof in its entirety by the following new Section 3.2.1:

3.2.1 Place of meetings

Meetings of shareholders shall be held at any place within Canada that the board of directors determines, or at any place outside Canada if such place is specified in the articles or all the shareholders entitled to vote at the meeting agree that the meeting is to be held at that place.

2. the amendment to By-law No. 1 of the Corporation relating to the conduct of internal affairs adding a new section 3.2.2as follow:

3.2.2 Meeting held by Electronic Means

Meetings of shareholders may be held entirely by means of telephonic, electronic or other communications facility that permits all participants to communicate adequately with each other during the meeting. Any person entitled to attend a meeting of shareholders, who, by any such means, participates in a meeting, is deemed for purposes of the Act to be present at the meeting. The directors may establish procedures regarding the holding of meetings of shareholders by such means in accordance with the Act.

Any person participating in a shareholders' meeting by any such means and who is entitled to vote at the meeting, may do so if the communication facility enables the vote to be gathered in a manner that permits its subsequent verification and that permits the tallied vote to be presented to the Company without it being possible for the Company to identify how the person voted.

be and is hereby approved, ratified and confirmed; and

any one director or officer of the Corporation be and is hereby authorized, for and on behalf of the Corporation, to execute and deliver all such documents and instruments and to do all such other acts or things as such person may determine to be necessary or advisable to give effect to this resolution, the execution of any such document or the doing of any other act or thing being conclusive evidence of such determination.